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Abstract
Background: RNA-specific adenosine deaminase ADAR1 is ubiquitously expressed in a variety of
mammalian cells and tissues. Although its physiological importance in non-nervous tissues has been
confirmed by analysis of null mutation phenotypes, few endogenous editing substrates have been
identified in numerous peripheral tissues and biological function of ADAR1 has not been fully
understood.
Methods: A conditional site-specific, ribozyme-based gene knock-down strategy was utilized to
study the function of full-length isoform of ADAR1 (p150 protein) in HeLa cell. Double-stable HeLa
cell lines were developed by transfecting HeLa Tet-On cells with a pTRE-derived plasmid that can
express a hammerhead ribozyme against mRNA of p150 ADAR1 isoform under induction
condition. Semi-quantitative RT-PCR and Western blotting were performed to measure the
expression of p150 in selected cell clones. Cell proliferation was evaluated by means of MTT assay
and growth curve analysis. Cellular morphological changes were observed under light microscope.
Flow Cytometry was used for cell cycle analysis. Growth rate of cell transplants in BALB/c nude
mice was also investigated.
Results: Both HeLa cell proliferation in vitro and the growth rate of transplanted HeLa cell-
derived tumors in nude mice in vivo were significantly inhibited due to reduced expression of
ADAR1 p150. Additionally, cell cycle analysis showed that cell progression from G1 phase to S
phase was retarded in the ADAR1 p150 suppressed cells.
Conclusion: Our results suggest that normal expression and functioning of p150 ADAR1 is
essential for the maintenance of proper cell growth. The mechanisms underlying ADAR1's action
might include both editing of currently unknown double-stranded RNAs and interacting with other
cellular dsRNA-related processes.
Background
Adenosine (A) to inosine (I) conversion catalyzed by ade-
nosine deaminases acting on RNA (ADAR) is an evolu-
tionally conserved process, occurring in organisms from
unicellular protozoa to humans [1,2]. Through site-spe-
cific modification of pre-mRNAs, this process provides an
important post-transcriptional mechanism for expanding
the functional diversities of RNA and protein products,
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such as those that encode the glutamate receptors and
serotonin receptors [3,4]. In contrast, nonspecific editing
is more frequent and has been considered mainly impli-
cated in host defense mechanisms [5].
Due to the use of different promoters, human ADAR1 has
two major variants: The full-length form p150 is expressed
from an interferon (IFN) -inducible promoter and pre-
dominantly localizes to cytoplasm. Use of a constitutive
promoter, in contrast, produces an N-terminally trun-
cated, predominantly if not exclusively nuclear p110 pro-
tein that is not induced by IFN [6,7]. Owing to its special
cytoplasmic location and elevated deaminating activity
during infection, IFN-inducible p150 is believed to play a
role in antiviral defense against viruses that replicate in
the cytoplasm [8,9].
The physiological importance of ADAR1 has been con-
firmed by phenotypic analysis of null mutants in previous
studies. Inactivation of ADAR1 gene has been reported to
cause lethality in ADAR1+/- chimeric mice and ADAR1-/-
embryos, along with severe impairment of liver structure
and reduced hepatocyte cell density [10-12]. The remark-
able observation that among many ADAR1 deleted
embryonic tissues that underwent apoptosis, the highest
level of apoptosis was within the liver and regions exhib-
iting excessive apoptosis in ADAR1-/-  embryos corre-
sponded to tissues expressing the highest levels of ADAR1
in wild-type embryos indicated an essential role of
ADAR1 in the normal development of non nervous tis-
sues [10]. Moreover, compared with wild-type MEF
(mouse embryonic fibroblasts) cells, ADAR1-/- MEF cells
were prone to apoptosis when subjected to serum depri-
vation, and expression of ADAR1 p150 increased signifi-
cantly in wild-type MEF cells during serum deprivation
[12], perhaps indicating a special requirement of ADAR1
p150 for cell survival.
Recently, Samuel and his colleagues reported that small
amount of ADAR1 p150 could be detected in almost all
tissues of healthy adult mice [13]. Expression of p150 was
found to be least abundant in brain tissue of normal mice,
and this seems somewhat correlated with the previous
observation that no abnormality was detected in ADAR1-
deleted embryonic brain [10-12]. They also found that
p150 is most abundant in liver of mice infected with Sal-
monella and where it is also the major form of ADAR1.
Taken together, these data suggest that endogenous
ADAR1 p150 protein may play a critical role in the normal
development and maintenance of bodily tissues, espe-
cially for liver. However, despite the ubiquitous expres-
sion of ADAR1 and the correlated large amount of I-
containing mRNA (I-mRNA) throughout the body
[1,14,15], as of yet, only a few genes with editing sites in
coding regions have been identified as endogenous sub-
strates of ADAR1 [3,4,16].
The expression and regulation of ADAR1 p150 in human
tissues has not been fully characterized thus far. In HeLa
cells, the simultaneous presence of two forms of ADAR1
has been confirmed by both Western-blotting and
immunofluorescence analysis [17,18]. In the present
study, by using a method based on hammerhead
ribozyme technique, we specifically knocked down the
expression of mRNA for p150 ADAR1 isoform in HeLa
cells and first revealed that endogenous p150 is necessary
for the proper control of cell proliferation.
Methods
Design and construction of recombinant vector
Based on the previously reported method [19], a hammer-
head ribozyme was designed to target the human ADAR1
mRNA (Genbank ACCESSION NM_001111.3 GI:
7669471) at position 206, which is included in coding
sequence of p150 ADAR1 protein but absent in that of
p110 protein. Consequently, cellular phenotypes associ-
ated with induced-expression of this specific ribozyme
would be absolutely caused by deficiency of p150 ADAR1
isoform. The designed ribozyme oligonucleotide 5'-
TGAGGGAA CTGATGAGTCCGTGAGGACGAA
ACCCCTGC 3' (The underlined are nucleotides comple-
mentary to the substrate) and the corresponding reverse
complementary strand were synthesized and annealed
after heating to 100°C for 2 min followed by a slow cool-
ing to room temperature. For inducible ribozyme expres-
sion in mammalian cells, the double-stranded DNA
fragments were subcloned into the Tet-On pTRE plasmid
(Clontech, Palo Alto, CA, USA) to form a vector desig-
nated as pTRE-ADAR1-Rz, which would release free
ADAR1-Rz transcripts in the presence of doxycycline
(Dox). The integrity of the constructs was confirmed by
enzymatic digestion and DNA sequencing.
Cell cultures and stable transfection
HeLa Tet-On cells (Clontech, Palo Alto, CA, USA) were
cultured in DMEM medium (Gibco, Gaithersburg, MD,
USA) supplemented with 10% fetal bovine serum, 100
IU/mL penicillin and 100 µg/mL streptomycin. Cells
grown in 10 cm dishes were co-transfected with pTRE-
ADAR1-Rz and pTK-Hyg plasmids, or pTRE and pTK-Hyg
plasmids, using Lipofectamine 2000 (Gibco, USA) trans-
fection method. Transfected cells were screened for hygro-
mycin (Hyg) resistance. The selected clones were
designated as HeLa-Rz cells (carrying both pTRE-ADAR1-
Rz and pTK-Hyg) or HeLa-p cells (carrying both pTRE and
pTK-Hyg). Positive clones were further analyzed for the
expression of p150 ADAR1 isoform in the absence/pres-
ence of Dox at a final concentration of 2 µg/ml by using
RT-PCR and Western blotting methods, respectively.BMC Cancer 2006, 6:282 http://www.biomedcentral.com/1471-2407/6/282
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RNA isolation and RT-PCR
Total RNA was extracted using the TriZol reagent (Invitro-
gen, Carlsbad, CA, USA) and reverse transcribed using
random hexamer primers and reverse transcriptase
(Superscript II, Invitrogen) at 43°C for 1 h. The cDNAs
prepared with RNAs obtained from different cell clones
were PCR-amplified using Taq DNA polymerase (Invitro-
gen) and the following ADAR1 specific primer pairs: 5'-
AGAAGGGCAAGCTACAGA -3' (nucleotides 742–759)
and 5'- AATTCAGGGCAGAGGAG -3' (nucleotides 1136–
1152) that flank exons 1–2 and capable of detecting tran-
scripts of ADAR1 p150 (Genbank ACCESSION
NM_001111.3 GI: 70166851) only. β-actin was also PCR-
amplified and used as an internal control. The PCR step
was performed for 23–32 cycles of denaturizing at 94°C
for 60 s, annealing at 55°C for 1 min, primer extension at
72°C for 1 min, and a final extension at 72°C for 10 min.
PCR products were analyzed by gel (1% agarose) electro-
phoresis analysis.
Western blotting
Total protein extracts of cultured cells obtained by using
Trizol reagent was prepared in SDS sample buffer and
used for Western-blotting analysis [17]. Samples contain-
ing 25 µg of total protein were fractionated by SDS-PAGE
on a 10% acrylamide gel and transferred onto a nitrocel-
lulose membrane. ADAR1 immunoreactivity was detected
using rabbit antiserum specific for the human ADAR1
protein (provided by Dr. Michael F. Jantsch of Depart-
ment of Chromosome Biology at University of Vienna) as
primary antibodies. Detection of antigen-antibody com-
plex formation was with HRP (horseradish peroxidase) –
conjugated goat anti-rabbit secondary antibody using an
ECL detection kit (Amersham Biosciences, Piscataway,
NJ).
Viability assessment
Cell viability was assessed using 3-(4, 5-dimethylthiazol-
2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) dye con-
version. Following Dox (2 µg/ml) exposure, MTT was
added to the wells to a final concentration of 1 mg/mL
and incubated at 37°C for 2 h. The reaction products were
solubolized overnight using 50 % dimethylformamide/20
% sodium dodecyl sulfate, and 96-well plates were read
on a plate reader (Molecular Probes, Sunnyvale, CA, USA)
at 590 nm. Viability was determined by comparison to
untreated cells. Cells were counted daily with a Coulter
Counter (Beckman Coulter, Fullerton, CA, USA). Mean
cell count data were then used to construct a growth curve
and the population doubling time was calculated as
reported previously [20]. The assessments were conducted
in triplicate.
Flow cytometry analysis
1 × 106 cells were harvested and resuspended in 100 µl of
the kit reaction buffer containing 5 µg/mL of propidium
iodide. After mixing, cells were incubated for 15 min in
the dark. Cell cycle analysis was performed on a Model
Coolper XL cytofluorimeter and analyzed by a Multicycle
Software. Experiments were run in triplicate.
Growth of cell transplants
BALB/c nu/nu nude mice aged 6–8 wks were obtained
from the Shanghai Institute of Materia Medica at the Chi-
nese Academy of Sciences in China. The experimental pro-
tocol was approved by the Experimental Animal Center of
Chinese Academy of Sciences (Identification No. Scfk11-
6A-0006). HeLa-Rz cells were grown in monolayer cul-
ture, harvested, washed twice, resuspended in Hank's Bal-
anced Salt Solution and implanted into the dorsal
subcutaneous tissue of mice by injection at 0.2 mL (1 ×
107 tumor cells for each animal). Animals were then ran-
domly divided into two groups: the ADAR1 knockdown
group (given drinking water containing 2.5 mg/mL of
Dox) and the control group. The tumor size was measured
twice a week with calipers and tumor volume was esti-
mated by the formula: (length × width2)/2 [21].
Statistical analysis
Data are expressed as mean ± standard deviation (SD).
Statistical comparisons were made using unpaired Stu-
dent's t-tests. A difference was considered significant at a
value of P < 0.05.
Results
HeLa Tet-On cells transfected with the constructed pTRE-
ADAR1-RZ or the control carrier were named as HeLa-Rz
and HeLa-P cell clones, respectively. A total of 24 HeLa-Rz
cell clones were collected and measured for Dox-induced
alteration in expression of mRNA of p150 ADAR1. The
relative abundance of ADAR1 p150 was similar for all cell
clones in the absence of Dox (data not shown). Addition
of 2 µg/ml of Dox significantly reduced the level of mRNA
of p150 ADAR1 isoform in a few HeLa-Rz cell clones, and
the inhibitory effect was in a time-dependent manner
(Fig. 1). The result of Western blotting analysis was shown
in Fig. 2: p150 isoform of ADAR1 was detected in both
HeLa-Rz cells and HeLa-P cells by the antibody we used.
After Dox treatment, the amount of p150 protein was
decreased significantly in HeLa-Rz cells, in contrast,
expression of p150 in HeLa-p cells was nearly not affected.
To reveal the potential correlations between level of p150
ADAR1 isoform and cellular biological properties, we
examined cell viability of different HeLa-Rz cell clones in
response to Dox treatment. The results showed that, in
addition to the decrease of p150 expression, relative cell
viability of HeLa-Rz clones was also reduced (with anBMC Cancer 2006, 6:282 http://www.biomedcentral.com/1471-2407/6/282
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inhibitory rate in the range of 25% to 38.0%) by three
days of Dox induction, whereas the viability of HeLa-p
cells was not affected by Dox treatment (Fig. 3A). A Dox-
induced downward shift in the cellular growth curve was
observed in a HeLa-Rz cell clone (shown in Fig. 3B). The
calculated population doubling time (Gt) (21.52 ± 1.20
h) of HeLa-Rz cells was prolonged (32.43 ± 3.40 h, P <
0.01) significantly by Dox treatment. However we did not
observed obvious morphological changes under the light
microscope.
HeLa-Rz cells were grown in medium containing 2 µg/mL
Dox for 48 h, causing the expression level of ADAR1
mRNA to decrease. Flow cytometry analysis detected a
constant increase in G1 DNA content (from 38.87 ± 0.11
% to 46.53 ± 0.10 %, p < 0.05) in comparison with the
control group. The percentage of cell DNA in replication
phase S slightly decreased, but statically the change was
not significant (39.94 ± 0.08 % vs 37.49 ± 0.07 %, p >
0.05). These data suggest that Dox treatment, acting
through knockdown of the p150 ADAR1 mRNA, could
lead to an arrest of cells in G1 phase, a delayed transition
into S phase, and eventually restrained proliferation of
cells (Fig 4). Under our experimental condition, Dox did
not induce apoptosis.
A single HeLa-Rz cell clone was picked out based on its
high sensitivity to Dox induction and the cells were cul-
tured. Nude mice were given subcutaneous injections of
cultured HeLa-Rz cells and the growth rate of cell trans-
plants was monitored. At 5 days post inoculation, all ani-
mals developed a palpable tumor at the injection site,
indicating the cell tumorigenecity was not altered. How-
ever the rate of tumor growth in the Dox-treated group
was significantly slower compared with the control group
(Fig. 5). This difference became detectable (P < 0.05) by
day 11. By day 23 the mean tumor size in Dox-treated
mice was 1.38 ± 0.34 cm3, whereas in the control group it
had reached 2.60 ± 0.69 cm3, which corresponding to an
about 60 % inhibitory rate of tumor growth. The health of
the mice was not affected as evaluated by the lack of body
weight loss. Taken together, these data indicate that
decrease of p150 ADAR1 isoform significantly inhibited
growth of transplanted HeLa-Rz cells, but does not affect
tumor induction in nude mice.
Effect of Dox induction on expression of p150 ADAR1 iso- form in HeLa cells Figure 2
Effect of Dox induction on expression of p150 
ADAR1 isoform in HeLa cells. Western blotting analysis 
of ADAR1 protein expression was performed on HeLa-Rz 
cells and HeLa-P cells treated with 2 µg/mL of Dox or left 
untreated respectively using methods described in the 
related text.
HeLa-Rz HeLa-P
Dox     0h 48h 0h   48h
p150
200 M
130
97
66
43
A. Effect of Dox induction on expression of mRNA for p150  isoform of ADAR1 in HeLa-Rz cells Figure 1
A. Effect of Dox induction on expression of mRNA 
for p150 isoform of ADAR1 in HeLa-Rz cells. B. 
Time-dependent knockdown of ADAR1 p150 gene in 
HeLa-Rz cells by Dox induction. RNA was isolated from 
HeLa-Rz cells treated with 2 µg/mL of Dox or left untreated 
and then was analyzed by RT-PCR. PCRs were carried out 
using primers that flank exons 1–2 of human ADAR1 mRNA 
(representing p150 isoform) or β-actin plus and minus prim-
ers, respectively. PCR products were analyzed by gel electro-
phoresis after the indicated number of amplification cycles.
A E-actin p150
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A. Effect of p150 isoform of ADAR1 knockdown on cell viability Figure 3
A. Effect of p150 isoform of ADAR1 knockdown on cell viability. Cells were cultured in the absence/presence of Dox 
for 72 h. 1~6: Different HeLa-Rz cell lines. HeLa-p cell line was used as a control (n = 10). * P > 0.05, ** P < 0.05, ***P < 0.01 
vs control. B. Effect of Dox on growth curve of HeLa-Rz cells. Cells were grown in media containing 2 µg/mL of Dox 
and the media was changed every two days. Data are expressed as mean ± SD (n = 6), *P > 0.05, ** P < 0.05, ***P < 0.01 vs 
control.
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Discussion
The sequences of ADAR1 from human, rat, and mouse are
highly conserved, all having a unique N-terminus (con-
taining two tandemly arranged Z-DNA-binding
domains), three double-stranded RNA-binding domains
(dsRBDs) and a conserved deaminase domain at the C-
terminus [6]. Its distinct structural architecture, tightly
regulated expression and intracellular distribution set
ADAR1 apart from other known ADAR gene family mem-
bers, ADAR2 and ADAR3 [22-24]. Furthermore, the dis-
crepancy between its widespread expression within the
body and the few known substrates indicates that in vivo
function of ADAR1 may not be restricted to nuclear pre-
mRNA editing [13,15,16].
Due to its interferon-inducible expression and its predom-
inantly cytoplasmic localization, p150 isoform of ADAR1
has been considered involved in host defense mecha-
nisms against viruses that replicate in the cytoplasm [8,9].
More recently, the observation that serum deprivation sig-
nificantly increased cytoplasmic level of p150 expression
in MEF cells suggests that p150 might also play a role crit-
ical for the promotion of cell survival [11].
In the present study, by using RT-PCR and Western blot-
ting methods, we demonstrated that endogenous p150
isoform (full-length isoform of human ADAR1) of
ADAR1 is expressed abundantly in HeLa cells. In order to
study its biological function, we specifically down regu-
lated the level of mRNA for p150 protein by using a ham-
merhead ribozyme-based technique. Our results revealed
that a several fold knockdown of ADAR1 p150 inhibited
cell proliferation (by a maximum inhibitory rate of 38%)
significantly. In addition, cell cycle progression of p150
suppressed cells was characterized by an excessive reten-
tion of cells in G1 phase and delayed transition into S
phase. However, we did not find any obvious cellular
morphological changes under the light microscope. In
nude mice, the growth rate of transplanted HeLa cells was
also significantly reduced by down-regulation of ADAR1
p150 expression.
The molecular mechanisms underlying the action of p150
ADAR1 protein to maintain cellular proliferation is still
under investigation. In vitro, the enzyme can act on
almost any double stranded substrate of sufficient length,
showing little site selectivity [25]. Secondly, because any
Cell cycle analysis of HeLa-Rz cells Figure 4
Cell cycle analysis of HeLa-Rz cells. Propidium iodide staining was performed and samples were analyzed by flow cytome-
try. A. Cell cycle of untreated cells. B. Cell cycle is altered after 48 h of Dox (2 µg/mL) treatment.
G1: 39.97%
S:  42.78%
G2: 17.25%
G1: 30.52%
S:  45.50%
G2: 23.97%
A BBMC Cancer 2006, 6:282 http://www.biomedcentral.com/1471-2407/6/282
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RNA that is at least partially double-stranded represents a
potential substrate for A-to-I editing, ADAR1 may inter-
fere with other cellular processes that rely on dsRNA mol-
ecules, such as RNAi [26] and NF90 proteins (including
NF110, NF90 and NF45) [23]. Finally, supported by the
observation that both expression and activity of ADAR1
p150 are elevated in lymphocytes in response to inflam-
mation [27], it appears that cytoplasmic editing activity of
ADAR1 p150 might also be involved in the regulation of
gene expression under special pathological conditions.
Based on our study, endogenous expression of ADAR1
p150 protein is necessary for the proper control of cell
growth. p150 protein is also capable of responding to
"unfavorable stimulations" and thus involved in host
defense mechanisms through its inducible expression,
cytoplasmic accumulation and shuttling activity between
the nuclear and cytoplasmic compartments [6,9,17,22].
Recent bioinformatics analysis has revealed that A-to-I
editing modification occurs in at least 30 different organs
with different frequencies and most editing events are
found within Alu elements embedded in the non-coding
regions of human transcriptome, which is suggested to be
engaged in the modulation of tumor cell growth and dif-
ferentiation [28-32]. Further investigation is required to
address the questions whether and which form of ADAR1
is associated with tumor development.
Conclusion
Our results suggest that normal expression and function-
ing of p150 ADAR1 isoform is essential for the mainte-
nance of proper cell growth. The mechanisms underlying
the action of ADAR1 p150 might include both cytoplas-
mic editing of currently unknown dsRNAs and interacting
with other cellular dsRNA-related processes.
Growth rate of HeLa-Rz cell transplants Figure 5
Growth rate of HeLa-Rz cell transplants. Nude mice received subcutaneous injection of 1 × 107 HeLa-Rz cells and ran-
domly grouped into the control or Dox treatment groups (2.5 mg/mL Dox in drinking water throughout the entire experimen-
tal period) (n = 8 for each group). * P > 0.05, ** P < 0.05, ***P < 0.01 vs control.
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